Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06729853 · ClinicalTrials.gov registry record · Phase 1
PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function
A Phase 1 study of Gout and Hyperuricemia, sponsored by Shanton Pharma Pte..
- Active
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 2
- Study locations
NCT06729853 is a Phase 1 study of Gout and Hyperuricemia that is active but no longer recruiting, run by Shanton Pharma Pte.. The registered enrollment target is 32 participants, below the 8,887-participant average among 34 other Gout trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06729853, a Phase 1 study of Gout and Hyperuricemia, is active but no longer recruiting, sponsored by Shanton Pharma Pte..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a multicenter, open-label, non-randomized, parallel-group, single-dose, 2-part, adaptive study in which up to approximately 32 adult subjects will be enrolled in one of 4 groups (8 subjects per group) with varying degrees of renal function.
Conditions Studied
Interventions
- DRUG SAP-001
Study Locations (2)
Florida
- Genesis Clinical Research - Tampa
Minnesota
- Nucleus Network Pty Ltd - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2024-04-24 |
| Est. Completion | 2025-04-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06729853
The ClinicalTrials.gov registry entry for NCT06729853 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 8,887-participant average among 34 other Gout trials with a reported enrollment target (100% lower). The listed sponsor is Shanton Pharma Pte., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Gout appearing as the primary indexed condition, and to 1 intervention - of which SAP-001 is the first listed.
NCT06729853 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06729853 about?
NCT06729853 is a clinical study titled "PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function". This is a multicenter, open-label, non-randomized, parallel-group, single-dose, 2-part, adaptive study in which up to approximately 32 adult subjects will be enrolled in one of 4 groups (8 subjects per group) with varying degrees of renal function.
What is the current status of trial NCT06729853?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2024-04-24. Estimated completion is 2025-04-28.
What conditions does trial NCT06729853 study?
This clinical trial studies the following conditions: Gout, Hyperuricemia.
What interventions are being tested in trial NCT06729853?
The interventions under investigation include: SAP-001 (DRUG).
Who is sponsoring clinical trial NCT06729853?
This trial is sponsored by Shanton Pharma Pte., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06729853 being conducted?
This trial has 2 study locations across Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gout
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Pharmacodynamics of SEL-037 (Pegsiticase) in Subjects With Elevated Blood Uric Acid Levels
COMPLETED · Phase 1
-
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia
COMPLETED · Phase 1
-
Mild, Moderate and Severe Renal Impairment Study
COMPLETED · Phase 1
-
The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults.
COMPLETED · Phase 1
-
NSAID Drug Interaction Study
COMPLETED · Phase 1
-
Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.